Drugs / SCYLLITOL
SCYLLITOL
also known as
ELND005 · AZD-103 · Cocositol · cyclohexane-1,2,3,4,5,6-hexol · Inositol, scyllo- · Quercinitol · Scyllo-cyclohexanehexol · scyllo-Inositol
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT01791725 | Sep 2013 → Jun 2014 | Down syndrome | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01766336 | Jan 2013 → Aug 2015 | Alzheimer disease | OPKO Health, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01735630 | Nov 2012 → May 2015 | Alzheimer disease | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01674010 | Aug 2012 → Jun 2014 | bipolar I disorder | OPKO Health, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00934050 | Jun 2009 → Jun 2011 | Alzheimer disease | OPKO Health, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00568776 Comparator | Dec 2007 → May 2010 | Alzheimer disease | OPKO Health, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-02-28 | Perrigo Company | Perrigo Company plc Announces The Transfer Of Development Asset ELND005 To Transition Therapeutics Inc. perrigo.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCYLLITOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL468154 ↗ |
| Known as | AZD-103 | “ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for AD.” NCT00568776 ↗ |
| Known as | Cocositol | ChEMBL registry synonym — accepted as the source's own label CHEMBL468154 ↗ |
| Known as | cyclohexane-1,2,3,4,5,6-hexol | “BACKGROUND: ELND005 (scyllo-Inositol; cyclohexane-1,2,3,4,5,6-hexol) has been evaluated as a potential disease-modifying treatment for Alzheimer's disease (AD).” PMID 28453471 ↗ 2017 |
| Known as | ELND005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01735630 ↗ |
| Known as | Inositol, scyllo- | ChEMBL registry synonym — accepted as the source's own label CHEMBL468154 ↗ |
| Known as | Quercinitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL468154 ↗ |
| Known as | Scyllo-cyclohexanehexol | ChEMBL registry synonym — accepted as the source's own label CHEMBL468154 ↗ |
| Known as | scyllo-Inositol | “BACKGROUND: ELND005 (scyllo-Inositol; cyclohexane-1,2,3,4,5,6-hexol) has been evaluated as a potential disease-modifying treatment for Alzheimer's disease (AD).” PMID 28453471 ↗ 2017 |
| Action | Inhibit | “ELND005 may prevent or inhibit the build up of amyloid protein in the brains of AD patients.” NCT00568776 ↗ |
| Modality | Small molecule | — CHEMBL468154 ↗ |
| Route | Oral | “ELND005 (formerly known as AZD-103), scyllo-inositol, is being investigated as an orally administered treatment for AD.” NCT00568776 ↗ |